These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1467198)

  • 1. Antiemetic study design: desirable objectives, stratifications and analyses.
    Olver IN
    Br J Cancer Suppl; 1992 Dec; 19():S30-3; discussion S33-4. PubMed ID: 1467198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetic studies: a methodological discussion.
    Olver IN; Simon RM; Aisner J
    Cancer Treat Rep; 1986 May; 70(5):555-63. PubMed ID: 3708607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetic study design: a discussion of Dr Olver's paper.
    Groshen S
    Br J Cancer Suppl; 1992 Dec; 19():S35-7. PubMed ID: 1467199
    [No Abstract]   [Full Text] [Related]  

  • 7. Measurement of success: parameters of efficacy.
    de Mulder PH
    Br J Cancer Suppl; 1992 Dec; 19():S68. PubMed ID: 1467205
    [No Abstract]   [Full Text] [Related]  

  • 8. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.
    Van Belle SJ; Cocquyt VF; Bleiberg H; Canon JL; Buyse M; Hulstaert F; De Witte M; De Keyser P; Westelinck K
    Anticancer Drugs; 1995 Feb; 6 Suppl 1():22-30. PubMed ID: 7749166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone in the treatment of nausea and vomiting from cancer chemotherapy.
    Winokur SH; Baker JJ; Lokey JL; Price NA; Bowen J
    J Med Assoc Ga; 1981 Apr; 70(4):263-4. PubMed ID: 7012258
    [No Abstract]   [Full Text] [Related]  

  • 11. Problems in antiemetic trial design and interpretation.
    Krasnow SH
    Oncology (Williston Park); 1989 Aug; 3(8 Suppl):5-10. PubMed ID: 2701576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim analyses in 2 x 2 crossover trials.
    Cook RJ
    Biometrics; 1995 Sep; 51(3):932-45. PubMed ID: 7548709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of nausea.
    Jenns K
    Cancer Nurs; 1994 Dec; 17(6):488-93. PubMed ID: 7820827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group.
    Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Andersson H; Hansen O; Sørensen BT; Räisänen I
    Anticancer Drugs; 1995 Feb; 6 Suppl 1():31-6. PubMed ID: 7749168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic therapy in patients treated with cisplatin chemotherapy.
    Roila F; Basurto C; Bracarda S; Del Favero A; Tonato M
    J Chemother; 1989 Jul; 1(4 Suppl):1281-5. PubMed ID: 16312866
    [No Abstract]   [Full Text] [Related]  

  • 20. Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
    Kris MG
    Important Adv Oncol; 1994; ():165-77. PubMed ID: 8206488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.